After a dip in the wake of the release of UnitedHealth Group's Q4 2024 earnings figures, shares in the company and other managed care insurers have largely bounced back.

Elevance Health posted $418 million in profit for the fourth quarter of 2024, a figure that surpassed Wall Street's expectations despite decreasing 51% year-over-year. | Elevance Health posted $418 million in profit for the fourth quarter of 2024,

Financial writer recommends buying Elevance Health stock despite recent drop, citing strong industry trends and potential for significant upside.

(Reuters) -Elevance Health on Thursday posted quarterly profit slightly above Wall Street expectations, helped by lower-than-expected spending on medical care for its members. The results lifted Elevance's shares more than 5% before the bell and also boosted peers such as Cigna and CVS Health.

The Indianapolis-based company said it had net income of $1.81 per share. Earnings, adjusted for one-time gains and costs, came to $3.84 per share. The results beat Wall Street expectations. The average estimate of 17 analysts surveyed by Zacks Investment Research was for earnings of $3.80 per share.

U.S. stocks are drifting near a record as Wall Street’s recent rally loses some momentum. The S&P 500 slipped 0.1% in early trading Thursday, a day after after pulling to the edge of its all-time high set in early December.

Elevance Health (ELV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Scott Fidel from

Health-care companies rose sharply amid strong earnings.

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%. It is anticipated ...

Elevance Health Inc. (ELV), while reporting weak fourth-quarter earnings below market estimates, on Thursday issued fiscal 2025

The headline numbers for Elevance Health (ELV) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

TD Cowen analyst Ryan Langston has maintained their bullish stance on ELV stock, giving a Buy rating on January 24.Invest with Confidence: